insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies
insitro announced a worldwide exclusive research collaboration agreement with AstraZeneca plc (NYSE: AZN) to discover novel targets and therapeutics in metabolic dysfunction‑associated steatohepatitis (MASH) and cardiomyopathies, under which insitro will…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
